Literature DB >> 11513449

Atrial defibrillation thresholds of electrode configurations available to an atrioventricular defibrillator.

M E Benser1, G P Walcott, C R Killingsworth, S D Girouard, M M Morris, R E Ideker.   

Abstract

INTRODUCTION: Little investigation has been conducted to assess the atrial defibrillation thresholds of electrode configurations using electrodes designed for internal ventricular defibrillation (right ventricle [RV], superior vena cava [SVC], and pulse generator housing [Can]) combined with coronary sinus (CS) electrodes. We hypothesized that a CS-->SVC+Can electrode configuration would have a lower atrial defibrillation threshold than a standard configuration for defibrillation, RV-->SVC+Can. We also tested the atrial defibrillation thresholds of five other configurations. METHODS AND
RESULTS: In 12 closed chest sheep, we situated a two-coil (RV, SVC) defibrillation catheter, a left-pectoral subcutaneous Can, and a CS lead. Atrial fibrillation was burst induced and maintained with continuous infusion of intrapericardial acetyl-beta-methylcholine chloride. Using fixed-tilt biphasic shocks, we determined the atrial defibrillation thresholds of seven test configurations in random order according to a multiple-reversal protocol. The peak voltage and delivered energy atrial defibrillation thresholds of CS-->SVC+Can (168+/-67 V, 2.68+/-2.40 J) were significantly lower than those of RV-->SVC+Can (215+/-88 V, 4.46+/-3.40 J). The atrial defibrillation thresholds of the other test configurations were RV+CS-->SVC+Can: 146+/-59 V, 1.92+/-1.45 J; RV-->CS+SVC+Can: 191+/-89 V, 3.53+/-3.19 J; CS-->SVC: 188+/-98 V, 3.77+/-4.14 J; SVC-->CS+ Can: 265+/-145 V, 7.37+/-9.12 J; and SVC-->Can: 516+/-209 V, 24.5+/-15.0 J.
CONCLUSIONS: The atrial defibrillation threshold of CS-->SVC+Can is significantly lower than that of RV-->SVC+Can. In addition, the low atrial defibrillation threshold of RV+CS-->SVC+Can merits further investigation. Based on corroboration of low atrial defibrillation thresholds of CS-based configurations in humans, physicians might consider using CS leads with atrioventricular defibrillators.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513449     DOI: 10.1046/j.1540-8167.2001.00957.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

1.  Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling.

Authors:  Thomas H Everett; Emily E Wilson; Sander Verheule; Jose M Guerra; Scott Foreman; Jeffrey E Olgin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-07-28       Impact factor: 4.733

2.  Internal atrial and ventricular defibrillation during electrophysiology procedures.

Authors:  Fred M Kusumoto
Journal:  J Interv Card Electrophysiol       Date:  2005-08       Impact factor: 1.900

3.  Transmural characteristics of atrial fibrillation in canine models of structural and electrical atrial remodeling assessed by simultaneous epicardial and endocardial mapping.

Authors:  Thomas H Everett; Emily E Wilson; George S Hulley; Jeffrey E Olgin
Journal:  Heart Rhythm       Date:  2010-01-11       Impact factor: 6.343

Review 4.  Intracardiac atrial defibrillation.

Authors:  Derek J Dosdall; Raymond E Ideker
Journal:  Heart Rhythm       Date:  2006-12-28       Impact factor: 6.343

5.  Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance.

Authors:  Andreas Schuchert; Giuseppe Boriani; Christian Wollmann; Mauro Biffi; Martin Kühl; Johannes Sperzel; Sascha Stiller; Gianni Gasparini; Dirk Böcker
Journal:  J Interv Card Electrophysiol       Date:  2005-03       Impact factor: 1.900

6.  Minimum energy single-shock internal atrial defibrillation in sheep.

Authors:  Amy M Goodman; Merlise A Clyde; Donald S Burdick; Salim F Idriss; Patrick D Wolf
Journal:  J Interv Card Electrophysiol       Date:  2004-04       Impact factor: 1.900

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.